Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Med Sci Sports Exerc ; 51(1): 84-93, 2019 01.
Artigo em Inglês | MEDLINE | ID: mdl-30113523

RESUMO

INTRODUCTION: Low-intensity endurance training (ET) performed with blood flow restriction (BFR) can improve muscle strength, cross-sectional area (CSA) and cardiorespiratory capacity. Whether muscle strength and CSA as well as cardiorespiratory capacity (i.e., V˙O2max) and underlying molecular processes regulating such respective muscle adaptations are comparable to resistance and ET is unknown. PURPOSE: To determine the respective chronic (i.e., 8 wk) functional, morphological, and molecular responses of ET-BFR training compared with conventional, unrestricted resistance training (RT) and ET. METHODS: Thirty healthy young men were randomly assigned to one of three experimental groups: ET-BFR (n = 10, 4 d·wk, 30-min cycling at 40% of V˙O2max), RT (n = 10, 4 d·wk, 4 sets of 10 repetitions leg press at 70% of one repetition maximum with 60 s rest) or ET (n = 10, 4 d·wk, 30-min cycling at 70% of V˙O2max) for 8 wk. Measures of quadriceps CSA, leg press one repetition maximum, and V˙O2max as well as muscle biopsies were obtained before and after intervention. RESULTS: Both RT and ET-BFR increased muscle strength and hypertrophy responses. ET-BFR also increased V˙O2max, total cytochrome c oxidase subunit 4 isoform 1 abundance and vascular endothelial growth factor mRNA abundance despite the lower work load compared to ET. CONCLUSIONS: Eight weeks of ET-BFR can increase muscle strength and induce similar muscle hypertrophy responses to RT while V˙O2max responses also increased postintervention even with a significantly lower work load compared with ET. Our findings provide new insight to some of the molecular mechanisms mediating adaptation responses with ET-BFR and the potential for this training protocol to improve muscle and cardiorespiratory capacity.


Assuntos
Ciclismo/fisiologia , Aptidão Cardiorrespiratória/fisiologia , Força Muscular/fisiologia , Resistência Física/fisiologia , Músculo Quadríceps/irrigação sanguínea , Fluxo Sanguíneo Regional , Treinamento Resistido/métodos , Adaptação Fisiológica , Biópsia , Complexo IV da Cadeia de Transporte de Elétrons/metabolismo , Humanos , Masculino , Consumo de Oxigênio , Músculo Quadríceps/anatomia & histologia , Músculo Quadríceps/diagnóstico por imagem , Músculo Quadríceps/fisiologia , RNA Mensageiro/metabolismo , Fluxo Sanguíneo Regional/fisiologia , Ultrassonografia , Fator A de Crescimento do Endotélio Vascular/metabolismo
2.
Sci Rep ; 7(1): 14876, 2017 11 01.
Artigo em Inglês | MEDLINE | ID: mdl-29093479

RESUMO

Disruption of insulin secretion and clearance both contribute to obesity-induced hyperinsulinemia, though reduced insulin clearance seems to be the main factor. The liver is the major site for insulin degradation, a process mainly coordinated by the insulin-degrading enzyme (IDE). The beneficial effects of taurine conjugated bile acid (TUDCA) on insulin secretion as well as insulin sensitivity have been recently described. However, the possible role of TUDCA in insulin clearance had not yet been explored. Here, we demonstrated that 15 days treatment with TUDCA reestablished plasma insulin to physiological concentrations in high fat diet (HFD) mice, a phenomenon associated with increased insulin clearance and liver IDE expression. TUDCA also increased IDE expression in human hepatic cell line HepG2. This effect was not observed in the presence of an inhibitor of the hepatic membrane bile acid receptor, S1PR2, nor when its downstream proteins were inhibited, including IR, PI3K and Akt. These results indicate that treatment with TUDCA may be helpful to counteract obesity-induced hyperinsulinemia through increasing insulin clearance, likely through enhanced liver IDE expression in a mechanism dependent on S1PR2-Insulin pathway activation.


Assuntos
Insulina/farmacocinética , Insulisina/efeitos dos fármacos , Fígado/enzimologia , Ácido Tauroquenodesoxicólico/farmacologia , Animais , Dieta Hiperlipídica , Células Hep G2 , Humanos , Hiperinsulinismo/tratamento farmacológico , Insulisina/metabolismo , Fígado/metabolismo , Camundongos , Camundongos Obesos
SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa